Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 biodistribution in bone metastatic CRPC
NCT04521361Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Radiopharmaceutical
- Countries
- 6
01
Overview
Phase 1, open-label trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Bayer. Primary endpoint: Area Under the Curve of radium-223 in tumor-free bone after 3 doses at 144 hours. Started Nov 2020; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04521361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521361.